Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial
What is the GMMG-CONCEPT trial?
The GMMG-CONCEPT trial is a clinical phase II, multicenter, open-label study which evaluates induction, consolidation, and maintenance treatment with the quadruplet regimen isatuximab plus carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma patients (HR MM pts).
In this video:
Dr. Katja Weisel (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) discusses the interim analysis of the GMMG-CONCEPT trial investigating solely high-risk multiple myeloma patients using the Isa-KRd quadruplet treatment. The initial report still shows significantly impaired prognostic outcomes. The Addition of CD38 monoclonal antibodies to standard-of-care regimens significantly improved response rates and depth of response in newly diagnosed and relapsed or refractory myeloma patients.
The overall safety profile of Isa-KRd is expected and consistent with previous reports. The study is ongoing, with patients continuing to be recruited.
Clinical trial information: NCT03104842.
KATJA WEISEL, MD
Dr. Katja Weisel is the Deputy Clinic Director and Senior Physician at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Visit Dr. Katja Weisel’s full biography.